Direct labelling of the human P2X 7 receptor and identification of positive and negative cooperativity of binding

British Journal of Pharmacology

Volumn 151, Issue 1, 2007, Pages 84-95

  Michel, A D ^a   Chambers, L J ^a   Clay, W C ^b   Condreay, J P ^b   Walter, D S ^a   Chessell, I P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

ATP; BzATP; KN62; P2X 7 receptor; PPADS; Radioligand binding; Suramin

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; ADENOSINE TRIPHOSPHATE; BRILLIANT BLUE; COMPOUND 17; DECAVANADIC ACID; LIGAND; N [2 [[2 [(2 HYDROXYETHYL)AMINO]ETHYL]AMINO] 5 QUINOLINYL] 2 TRICYCLO[3.3.1.1 3,7 ]DEC 1 YLACETAMIDE; PURINE P2X7 RECEPTOR; PURINE P2X7 RECEPTOR ANTAGONIST; SODIUM CHLORIDE; TRITIUM; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; IOHEXOL; PURINE P2 RECEPTOR; VANADIC ACID;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIGAND BINDING; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCATCHARD PLOT; BINDING SITE; CELL CULTURE; KINETICS; METABOLISM; METHODOLOGY; RADIOASSAY;

ADENOSINE TRIPHOSPHATE; BINDING SITES; CELLS, CULTURED; HUMANS; IOHEXOL; KINETICS; RADIOLIGAND ASSAY; RECEPTORS, PURINERGIC P2; TRITIUM; VANADATES;

EID: 34247646953     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707196     Document Type: Article

References (38)

1. Ames R, Nuthulaganti P, Fornwald J, Shabon U, van-der-Keyl H, Elshourbagy N (2004). Heterologous expression of G protein-coupled receptors in U-2 OS osteosarcoma cells. Receptors Channels 10: 117-124.
2. 2 and heteromeric P2X1 + 2 receptor subtypes. J Mol Biol 342: 333-343.
3. 6 receptors do not oligomerize. J Biol Chem 280: 10759-10765.
4. Bean BP (1992). Pharmacology and electrophysiology of ATP-activated ion channels. Trends Pharmacol Sci 13: 87-90.
5. Beigi RD, Kertesy SB, Aquilina G, Dubyak GR (2003). Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br J Pharmacol 140: 507-519.
6. Bianchi BR, Lynch KJ, Touma E, Niforatos W, Burgard EC, Alexander KM et al. (1999). Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol 376: 127-138.
7. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M et al. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272: 22330-22339.
8. 7 receptor function with a monoclonal antibody. Blood 92: 3521-3528.
9. Chamness GC, McGuire WL (1975). Scatchard plots: common errors in correction and interpretation. Steroids 26: 538-542.
10. 7 receptor. Br J Pharmacol 124: 1314-1320.
11. Clay WC, Condreay JP, Moore LB, Weaver SL, Watson MA, Kost TA et al. (2003). Recombinant baculoviruses used to study estrogen receptor function in human osteosarcoma cells. Assay Drug Dev Technol 1: 801-810.
12. Cockcroft S, Gomperts BD (1979). ATP induces nucleotide permeability in rat mast cells. Nature 279: 541-542.
13. Condreay JP, Witherspoon SM, Clay WC, Kost TA (1999). Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci USA 96: 127-132.
14. De Lean A, Munson PJ, Rodbard D (1979). Multi-subsite receptors for multivalent ligands. Application to drugs, hormones, and neurotransmitters. Mol Pharmacol 15: 60-70.
15. De Lean A, Rodbard D (1979). Kinetics of cooperative binding. Receptors: Comprehensive Treatise O'Brien RD (ed). New York: Plenum, Vol 1, Chapter 4, pp 143-192.
16. Egan TM, Samways DSK, Li Z (2006). Biophysics of P2X receptors. Pflügers Arch 452: 501-512.
17. Evans RJ, Lewis C, Buell G, Valera S, North RA, Surprenant A (1995). Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2X purinoceptors). Mol Pharmacol 48: 178-183.
18. Ford R, Leroux F, Stocks M (2003). Preparation of (adamantyl)(quinolinyl) amides as P2X7 receptor antagonists. PCT Int Appl, 171 pp. WO 2003080579 A1.
19. Franco R, Casado V, Mallol J, Ferre S, Fuxe K, Cortes A et al. (2005). Dimer-based model for heptaspanning membrane receptors. Trends Biochem Sci 30: 360-366.
20. Gargett CE, Wiley JS (1997). The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Br J Pharmacol 120: 1483-1490.
21. Gever J, Cockayne D, Dillon M, Burnstock G, Ford APDW (2006). Pharmacology of P2X channels. Pflügers Arch 452: 513-537.
22. Hibell AD, Thompson KM, Xing M, Humphrey PP, Michel AD (2001). Complexities of measuring antagonist potency at P2X(7) receptor orthologs. J Pharmacol Exp Ther 296: 947-957.
23. 7 nucleotide receptor: high selectivity for the human versus the rat receptor homologues. Mol Pharmacol 54: 22-32.
24. Jiang LH, Mackenzie AB, North RA (2000). Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors. Mol Pharmacol 58: 82-88.
25. Michel AD, Chessell IP, Humphrey PP (1999). Ionic effects on human recombinant P2X7 receptor function. Naunyn Schmied Arch Pharmacol 359: 102-109.
26. Michel AD, Kaur R, Chessell IP, Humphrey PP (2000). Antagonist effects on human P2X(7) receptor-mediated cellular accumulation of YO-PRO-1. Br J Pharmacol 130: 513-520.
27. Michel AD, Miller KJ, Lundstrom K, Buell GN, Humphrey PP (1997). Radiolabeling of the rat p2x4 purinoceptor: evidence for allosteric interactions of purinoceptor antagonists and monovalent cations with p2x purinoceptors. Mol Pharmacol 51: 524-532.
28. Michel AD, Thompson KM, Simon J, Boyfield I, Fonfria E, Humphrey Patrick PA (2006b). Species and response dependent differences in the effects of MAPK inhibitors on P2X7 receptor function. Br J Pharmacol 149: 948-957.
29. Michel AD, Xing M, Thompson KM, Jones CA (2006a). Decavanadate, a P2X receptor antagonist, and its use to study ligand interactions with P2X7 receptors. Eur J Pharmacol 534: 19-29.
30. Montminy MR, Sevarino KA, Wagner JA, Mandel G, Goodman RH (1986). Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. Proc Natl Acad Sci USA 83: 6682-6686.
31. Murgia M, Hanau S, Pizzo P, Rippa M, Di Virgilio F (1993). Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. J Biol Chem 268: 8199-8203.
32. North RA (2002). Molecular physiology of P2X receptors. Physiol Rev 82: 1013-1067.
33. 2+ channels is simply explained by competition for individual attachment points. J Biol Chem 268: 18580-18585.
34. Rassendren F, Buell GN, Virginio C, Collo G, North RA, Surprenant A (1997). The permeabilizing ATP receptor, p2x7. Cloning and expression of a human cDNA. J Biol Chem 272: 5482-5486.
35. Romagnoli R, Baraldi PG, Di Virgilio F (2005). Recent progress in the discovery of antagonists acting at P2X7 receptor. Expert Opin Ther Patents 15: 271-287.
36. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G (1996). The cytolytic p-2z receptor for extracellular ATP identified as a p-2x receptor (p2x(7)). Science 272: 735-738.
37. 7 receptor. Neuropharmacol 36: 1285-1294.
38. Wiley JS, Chen R, Wiley MJ, Jamieson GP (1992). The ATP4-receptor- operated ion channel of human lymphocytes: inhibition of ion fluxes by amiloride analogs and by extracellular sodium ions. Arch Biochem Biophys 292: 411-418.